ALSO NOTED: FDA staffers back Ketek; Abbott gains a majority of Kos shares; and much more...

> In advance of an FDA advisory committee meeting on the controversial antibiotic Ketek, agency staffers have concluded that the data on the Sanofi-Aventis therapy demonstrates that it is safe and effective. Report

> Abbott's cash tender offer has won a majority of Kos Pharmaceuticals' shares. Report

> Amgen plans to repurchase up to $5 billion of its stock. Release

> Biomira has arranged $13 million in financing. Release

> Athenagen has begun a Phase II clinical study of the company's lead compound, GTS-21, in patients with Alzheimer's disease. Release

> OncoMethylome Sciences has licensed its prostate cancer test to a subsidiary of Johnson & Johnson. Report

> Eden Bioscience has received a delisting notification from Nasdaq. Report

And Finally… A new study says that a sleep apnea therapy also improves memory. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.